Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Angiogenesis is integral to tumour growth and invasion, and is a key target for cancer therapeutics. However, for many of the licensed indications, only a modest clinical benefit has been observed for both monoclonal antibody and small-molecule tyrosine kinase inhibitor anti-angiogenic therapy. Pre-clinical and clinical studies have attempted to evaluate circulating, imaging, genomic, pharmacokinetic, and pharmacodynamic markers that may aid both the selection of patients for treatment and define dosing. Correct dosing is likely to be critical in the context of vascular normalization to allow better delivery of concomitant anti-cancer therapy and novel imaging techniques hold much promise in the early evaluation of pharmacodynamic response to improve efficacy.

Original publication

DOI

10.1007/s13318-017-0442-x

Type

Journal article

Journal

Eur J Drug Metab Pharmacokinet

Publication Date

04/2018

Volume

43

Pages

137 - 153

Keywords

Animals, Antibodies, Monoclonal, Antineoplastic Agents, Biomarkers, Tumor, Humans, Neoplasms, Neovascularization, Pathologic, Protein Kinase Inhibitors